This is risky business. Only invest what you can afford to lose.
Followers | 0 |
Posts | 1,505 |
Boards Moderated | 0 |
Alias Born | 02/27/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.016 x .018. UBSS stacked high at bid. We just need juice to take a swing at .018...
Haha! This is why I wish IHUB had a like button for comments. VYCO really does give you some interesting things to talk about. This is the first ticker I've been in on that actually offers to restore lost vision. Good stuff!
I welcome all volume, but daytrading is not really the name of the game here. The story is way too solid. We need some more solid longs looking to see a nice solid return on a 3 to 6 month hold
VYCO International Distributors:
Australia
Aurora BioScience Pty Ltd
Mandy Crispin - Darren Banks
P: +61 (0) 408-404-150
PKR China
Devon International
John Bennet, Ruth Wu, John Bai
P: 1-800-251-7488
Greece
KK Medical Specialist
Katerina Katsamba
P: +30 (210) 6717009
Italy
TekMed Instruments S.P.A
Claudio Settembre, Fulvio Albano, Rosella Barchetta
P: +39 (02) 577892.1
Japan
Medical U&A Inc
Al Tsukimoto
P: (06) 4796-3151
The Netherlands / some of Germany
Circle Medical BV
Hans Weynschenk, Neils Weynschenk
P: +0031 246453131
South Korea
Meson Corporation
James Lee
P: 82-02-2057-6118
Spain
Susministros Hospitalirios SA
Stephen Whitehouse
P: 00-34-934607920
Sweden
P.O. Medica AB
Richard Leo
P: +46 33 266800
Switzerland
SomaPharm AG
Manfred Weisser
P: +41 041-760-0745
United Kingdom
Neurotechnics Limited
Ian Graney
P: 0845 450 0590
VYCO USA distributors:
Alabama Kentucky North Dakota
Alaska Louisiana Ohio
Arizona Maine Oklahoma
Arkansas Maryland Oregon
California (northern) Massachusetts Pennsylvania (east)
California (southern) Michigan Pennsylvania (west)
Colorado Minnesota Rhode Island
Connecticut Mississippi South Carolina
Delaware Missouri South Dakota
Dist. of Columbia Montana Tennessee
Florida Nebraska Texas
Georgia Nevada Utah
Hawaii Vermont Virginia (northern)
Idaho (eastern) New Hampshire Virginia (central & southern)
Idaho (western) New Jersey (north) Washington
Illinois New Jersey (south) West Virginia
Indiana New Mexico Wisconsin
Iowa New York Wyoming
Kansas North Carolina
"VYCOR Should Enter Hyper-growth During the Next Two to Three Years. Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVisionsubsidiary, as its products have no real competition and address a global market that could be up to $20B in size. Although NovaVision's products could require several years to achieve market penetration of even 5%, this would still equate to a huge win for a company of this size. Both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States." -- from the Harbinger Report
$1B+ Market Opportunity - First Real Treatment for Stroke-Related Vision Loss
Vycor's NovaVision helps victims of stroke and traumatic-brain injury permanently regain a
key portion of lost vision-field. This is the first treatment for what has been considered a
permanent and irreversible condition, and is backed by a strong scientific team, 15 years of
research and 20 clinical studies. It is FDA 510(k) cleared, has a strong patent portfolio, and
addresses a very large market in the United States, Europe, and around the world. Although
we believe it will take NovaVision several years to penetrate a big percentage of this market,
its multi-billion dollar size makes this product line a potential blockbuster for Vycor.
• ViewSite Helps Neurosurgeons Address "Inoperable" Cases and Improves Outcomes
The transparent ViewSite Brain Access System (VBAS) dramatically reduces the damage
caused by "retractors" that surgeons now use to reach sub-surface areas of the brain. It also
provides these surgeons with superior visibility during surgical procedures. The net effect of
this is improved clinical outcomes, shorter surgeries, and shorter recovery times; in some cases
this product's superior attributes have allowed brain surgeons to successfully perform surgeries
that would have otherwise been considered inoperable. The VBAS is protected by a strong
patent portfolio, and we believe its clinical superiority and cost savings will lead it to become
the de facto standard in surgical devices for neurosurgery over the next few years.
• The Company Should Enter Hyper-growth During the Next Two to Three Years
Vycor's ViewSite is already making good inroads into the relatively small neurosurgery
market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early
2013. However, we are most excited about the long-term potential of the NovaVision
subsidiary, as its products have no real competition and address a global market that could be
up to $20B in size. Although NovaVision's products could require several years to achieve
market penetration of even 5%, this would still equate to a huge win for a company of this size.
Both NovaVision and ViewSite have strong patent protection and backing from the scientific
community, and both are FDA 510(k) cleared for sale in the United States.
• We Believe an Investment in Vycor is Somewhat Risky but Has Exceptional Potential
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
foresee.
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO: where to today??
Its details like that that keep longs salivating for this play to mature
We've got some strong support at .016. Bid sitters waiting for some to come down from .018 and ring their bargain bell
Great post, LB: "Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car."
Add to all of this a $10B industry and 200% rev increase and you have some nice gains cooking
VYCO ingredients add up to my kind of recipe: strong patent suit, exclusive FDA approval, NovaVision cure for stroke related sight loss, ViewSite enabling once inoperable brain surgeries, less intrusive, faster recovery
Excited to see what VYCO does today.
More Personmarks Please! And I will mark back quicker this time ;0D
Like your board, just followed
Have you checked out VYCO yet? Its been getting alot of attention out of nowhere in last several days. This last Friday it was #2 on Ihub breakout boards with 14x 's avg volume. ZERO promo going on, just grassroots investor confidence reaching a tipping point.
A few reasons why:
-NovaVision Technology: ONLY FDA approved treatment that actually restores vision to stroke patients, something thought previously impossible. Patent protected. Already successfully treated 2,000 patients.
-ViewSite Technology makes previously impossible brain surgeries operable. Less invasive, shorter recovery times. Has been used to perform over 3,000 brain surgery procedures, in 130 US hospitals
-$20B market. $50 mm already spent to bring to market.39% of sales comes from sales outside US
-Revenues up 198%. Forecasts call for $2.9mm in revs in 2012, $5.3m in 2013
-Kenneth Coviello as CEO has led many other successful medical device companies with combined sales of $350mm
-Strong backing from Scientific community. Harvard medical school profs on the advisory board
Yeah, its up to investors to get the word out, no promo campaign to lean on. So far when a savvy investor gets a nudge in this direction, he is gripped by the opportunity. Lots of OTCBB gurus are buying and holding. I'm continuing to rattle cages and spread the word
"Executive management includes, amongst other industry tenured power players, Kenneth T. Coviello as CEO and Director. Mr. Coviello has had 25 years of experience in building profitable medical device companies. He has served on senior leadership teams for companies with a combined total of $350MM in sales."
http://ir.vycormedical.com/profiles/investor/Management.asp?BzID=2090
"The NovaVision advisory board reflects the caliber of international medical luminaries who resoundingly support Vycor's breakthrough technology. Alvaro Pascual-Leone, MD PhD is Professor of Neurology at Harvard Medical Shool. He is one of many highly respected medical leaders who warmly commend Vycor technology to their patients and peers
http://www.novavision.com/advisory-board-alvaro-pascual-leone
"Revenue up 198% Over First Quarter 2011; Vycor Medical Division Revenue up 222% Over 2011, NovaVision Division up 145%; Net Loss Reduced"
VYCO is seriously undervalued:
"VYCOR Should Enter Hyper-growth During the Next Two to Three Years. Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVisionsubsidiary, as its products have no real competition and address a global market that could be up to $20B in size. Although NovaVision's products could require several years to achieve market penetration of even 5%, this would still equate to a huge win for a company of this size. Both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States." -- from the Harbinger Report
VYCO Mega organic grassroots bombshell developing before our very eyes:
- $10B market
-Patents held exclusive
-Only FDA approved treatment for stroke related blindness
-200% increase in revs
~VYCO~ moving again, 1 mm to .019, get in before the pullback is done
Looks like some good support at .016. At least we're thinner going to .019 than down at this point
~VYCO~ FDA approved cure for stroke related blindness. You cannot afford to ignore this. http://player.vimeo.com/video/39903199
~VYCO~ Big grassroots undercurrent of investor support in the making. Seriously undervalued. 200% gain in revenue posted. $10b industry. Exclusive patents to the only FDA approved cure for blindness related to stroke. That's right. Cures blindness. Don't let this pass you by.
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
~VYCO~ How many true investments have you seen in penny stocks? "The benefit for investors entering at this juncture is that a lot of that difficult technology evangelizing has
already occurred, and sales acceleration could well begin sooner rather than later. Vycor acquired NovaVision
after its previous management spent $50 million on developing and commercializing the product. This included
funds spent on targeting leading neurotherapy institutions, conducting clinical studies for technology-validation
purposes, and garnering patient testimonials; we believe NovaVision is now in a to leverage these expenditures
into strong market penetration. This should be especially true once the Web-based product launches, and overall
we feel that VYCO shares represent an excellent current value based on our expectations the future results."
VYCO: only FDA approved treatment for stroke related vision loss. The DD here will blow you away. A steal right now:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO grassroots organic swell of investor awareness bearing fruit soon. Fantastic fundamentals and undervalued:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO defines hidden gem. Buy at the lull:
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO pullback. Not going any lower. Right time to invest:
"The benefit for investors entering at this juncture is that a lot of that difficult technology evangelizing has
already occurred, and sales acceleration could well begin sooner rather than later. Vycor acquired NovaVision
after its previous management spent $50 million on developing and commercializing the product. This included
funds spent on targeting leading neurotherapy institutions, conducting clinical studies for technology-validation
purposes, and garnering patient testimonials; we believe NovaVision is now in a to leverage these expenditures
into strong market penetration. This should be especially true once the Web-based product launches, and overall
we feel that VYCO shares represent an excellent current value based on our expectations the future results."
VYCO: moving sideways this morning. Great time to get in.
http://player.vimeo.com/video/39903199
At least I got some of my .013's filled, nothing like a good deal,I don't imagine I'll get many more steals like that..
"The net result of our forecasts are revenues of $971k in FY11 growing to $2.9mm in FY12 and $5.3mm in
FY13. Operating income is expected to improve from ($4.6M) in FY11 to ($2.2M) in FY12, and to
($0.5mm) in FY13. Our model forecasts operating cash flows of ($2.8M) in FY11, ($1.8M) in FY12 and
($0.3mm) in FY13. This progression represents significant growth in revenues and improvement in cash
flows that will figure highly in valuation assumptions, and will potentially lead to profitability in 2014."
Can anyone say: "Bargain Basement steal?"
Kenneth Coviello, the CEO, knows how to lead Revenue Generating medical equipment company's:
Kenneth Coviello, CEO and Director
• Over 35 years of medical device industry experience
• President of Lumex, a medical device company with $50m in sales
• Senior VP of Graham Field, a medical device company with $300m in sales
• Senior VP of Misonix Medical (NASDAQ Ticker: MSON), a developer of ultrasonic technology
with $45m in sales
"VYCOR Should Enter Hyper-growth During the Next Two to Three Years. Vycor's ViewSite is already making good inroads into the relatively small neurosurgery market, both in the U.S. and overseas, and we expect sales to grow robustly beginning in early 2013. However, we are most excited about the long-term potential of the NovaVisionsubsidiary, as its products have no real competition and address a global market that could be up to $20B in size. Although NovaVision's products could require several years to achieve market penetration of even 5%, this would still equate to a huge win for a company of this size. Both NovaVision and ViewSite have strong patent protection and backing from the scientific community, and both are FDA 510(k) cleared for sale in the United States." -- from the Harbinger Report
VYCO VRT treatment has already treated 2,000 patients. A $170,000 shipment was made to China in December, 2011. VYCO technology is already being used in hundreds of hospitals worldwide.
Vycor distributors are international, and aside from the US, include Australia, China, Japan, the Benelux, Greece, Italy, Spain, Sweden and the UK. 39% of revenue comes from sales outside the US, 32% of which is China. http://www.vycormedical.com/products/distributors.html
"The benefit for investors entering at this juncture is that a lot of that difficult technology evangelizing has
already occurred, and sales acceleration could well begin sooner rather than later. Vycor acquired NovaVision
after its previous management spent $50 million on developing and commercializing the product. This included
funds spent on targeting leading neurotherapy institutions, conducting clinical studies for technology-validation
purposes, and garnering patient testimonials; we believe NovaVision is now in a to leverage these expenditures
into strong market penetration. This should be especially true once the Web-based product launches, and overall
we feel that VYCO shares represent an excellent current value based on our expectations the future results."
I agree, just a couple little taps on the Bid makes a big difference at this stage. But little pullbacks like this won't mean much as VYCO executes on market penetration for NoraVision and ViewSite
We need to see that spread close. VYCO is thin either way premarket. Someone needs to whack that ASK right out the gate imo